• 1
    Crotty B, Jewell P. Drug therapy of ulcerative colitis. Br J Clin Pharmacol 1992; 34: 18998.
  • 2
    Ewe K. Crohn disease and ulcerative colitis – newer therapeutic approaches. Z Gastroenterol 1993; 31: 1515.
  • 3
    Selby W. Current management of inflammatory bowel disease. Gastroenterol Hepatol 1993; 8: 7083.
  • 4
    Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 1989; 38: 50025.
  • 5
    Dallegri F, Ottonello L, Ballestrero A, Bogliolo F, Ferrando F, Patrone F. Cytoprotection against neutrophil derived hypochlorous acid: A potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis. Gut 1990; 31: 1846.
  • 6
    Yamada T, Volkmer C, Grisham MB. Antioxidant properties of 5-ASA: potential mechanism for its anti-inflammatory activity. Can J Gastroenterol 1990; 4: 295302.
  • 7
    Tamal H, Kachur JF, Grisham MB, Gaginella TS. Scavenging effect of 5-aminosalicylic acid on neutrophil-derived oxidants – possible contribution to the mechanism of action in inflammatory bowel disease. Biochem Pharmacol 1991; 41: 10016.
  • 8
    Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992; 33: 92932.
  • 9
    Palapies D, Peskar BA, Peskar BM. Interaction of 5-aminosalicylic acid with nitric oxide on rat aortic strips and human platelets. Eur J Pharmacol 1995; 28: 1459.
  • 10
    Kaiser GC, Yan F, Polk DB. Mesalazine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology 1999; 116: 6029.
  • 11
    Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K. Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000; 95: 34527.
  • 12
    Klotz U, Maier K. Chronisch-entzündliche Darmerkrankungen - Behandlung mit einer neuen Substanz. Therapiewoche 1985; 35: 3895903.
  • 13
    Maier K, von Gaisberg U, Klotz U. 5-Aminosalicylsäure-Tabletten (Salofalk, Claversal). Verdauungskrankh 1985; 3/6: 25960.
  • 14
    Hetzel DJ, Shearman DJC, Bochner F, et al. Azodisalicylate (Olsalazine) in the treatment of active ulcerative colitis. A placebo controlled clinical trial and assessment of drug disposition. Gastroenterol Hepatol 1986; 1: 25766.
  • 15
    Meyers S, Sachar DB, Present DH, Janowitz HD. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant to sulfasalazine. A prospective, randomized placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 1987; 93: 125562.
  • 16
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 826.
  • 17
    Sutherland LR, Robinson M, Onstad G, et al. A double-blind placebo-controlled multicentre study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 1990; 4: 4637.
  • 18
    Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis. Results of a controlled trial. Am J Gastroenterol 1993; 88: 118897.
  • 19
    Munakata A, Yoshida Y, Muto T, Tschuchiya S, Fukushima T, Hiwatashi N. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30: 10811.
  • 20
    Kruis W, Bar Meir S, Feher J, Stolte M. Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis. Gastroenterology 2000; 118 (Suppl 2): A780.
  • 21
    Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther 2003; 17: 11639.
  • 22
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 826.
  • 23
    Fredd S. Standards for approval of new drugs for IBD. Inflamm Bowel Dis 1995; 1: 28494.
  • 24
    Sutherland LR, Roth DE, Beck PL. Alternatives to sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bow Dis 1997; 3: 6578.
  • 25
    Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dose-finding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 3916.
  • 26
    Ewe K, Press AG, Oestreicher M. Effect of food intake on gastric emptying of gastric juice-resistant tablets and capsules. Dtsch Med Wsch 1992; 117: 28790.
  • 27
    Kruis W, Brandes J-W, Schreiber S, et al. Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. Aliment Pharmacol Ther 1998; 12: 70715.
  • 28
    Sninski CA, Cort DH, Shanahan F, et al. Oral mesalazine (Asacol) for mildly to moderately active ulcerative colitis. Ann Int Med 1991; 115: 3505.